Second New Interferon Drug Combo Cures Hepatitis C
WebMD News Archive
May 22, 2001 (Atlanta) -- Cure is not a word used lightly by doctors, researchers, or patients. But here at the Digestive Disease Week conference, the word is being used in connection with two combination therapies for hepatitis C.
Last fall, there was a report that a more active, once-weekly form of a drug called interferon -- when combined with the antiviral drug ribavirin -- appears to cure more than half of the people with hepatitis C virus who participated in the study. Now, new findings presented at the conference show that a second version of this interferon, combined with ribavirin, also works well to treat hepatitis C.
The new interferons are called "pegylated" versions, because they are linked to a chemical called polyethylene glycol, or PEG. This makes the drugs stay in the body much longer. Instead of the frequent injections needed for standard interferon, a patient needs only one shot per week of the new PEG-interferons. But that's not the only difference -- the PEG-interferons work much better than standard interferon both alone and in the current state-of-the-art combination with ribavirin.
The FDA already has approved PEG-Intron, made by Schering. The new findings reported here show that Pegasys, made by Roche, works about as well as PEG-Intron in combination with ribavirin. Overall, 56% of patients who got the new Pegasys/ribavirin combination were still hepatitis C negative 24 weeks after taking the drugs for 48 weeks. This is close to the 61% of patients who had a sustained response to Schering's PEG-Intron/ribavirin combination in an earlier study, in which dosages of the PEG-interferon were adjusted for patients' body weight.
"And sustained response means clearance of the virus with [the body's own] normal liver enzymes six months after the end of treatment, which at that point implies a cure," says Michael W. Fried, MD, who reported the new Pegasys/ribavirin findings. Fried is director of clinical hepatology at the University of North Carolina, Chapel Hill.
But the treatment is no trip to the beach. Just ask 22-year-old Miami resident Jennis Marichal, who got hepatitis C from a blood transfusion when she was a baby.